Singapore HSA Brief

Headline

HSA Singapore identifies undeclared potent corticosteroid in herbal product linked to iatrogenic Cushing's Syndrome

Executive Summary

The Health Sciences Authority of Singapore issued a press release on May 20, 2026, reporting that an elderly woman developed Cushing's Syndrome after consuming an herbal product found to contain an undeclared potent corticosteroid. HSA confirmed the product was adulterated and issued a public warning against its purchase or consumption.

Key Regulatory Signals

• Adulterated Product Identification: HSA confirmed the implicated herbal product contained an undeclared potent corticosteroid, constituting adulteration under Singapore's Health Products Act (Cap. 122D).
• Consumer Safety Alert: HSA directed the public to cease purchase and consumption of the identified product immediately, consistent with its standing enforcement posture on adulterated health products.
• Adverse Event Reporting: The case was identified through HSA's pharmacovigilance and adverse event reporting framework, underscoring the agency's active post-market surveillance function for health products including traditional medicines.
• Regulatory Compliance Trigger: Importers, distributors, and retailers handling herbal and traditional medicine products face renewed scrutiny obligations to verify product composition against registered formulations under the Health Products Act.

Regulatory Delta

This action is consistent with HSA's established enforcement pattern against adulterated traditional medicines and herbal products, continuing a posture documented across multiple prior HSA alerts in 2024 and 2025 involving undeclared steroids and pharmaceutically active substances in complementary health products. The structural departure here is the documented clinical outcome — iatrogenic Cushing's Syndrome — which elevates the adverse event severity profile beyond typical HSA adulteration alerts and may inform future post-market surveillance prioritization for corticosteroid-adulterated products. No cross-agency coordination signal or pending legislative trajectory is identified in the source release; HSA acted under its existing Health Products Act authority without reference to MAS, MOH rulemaking, or regional regulatory coordination.

Materiality Classification

MEDIUM — A single-product consumer safety enforcement action with public warning. Peer firms in the complementary health product, herbal medicine import, and traditional medicine distribution sectors face heightened scrutiny obligations, but no new binding rule or sector-wide structural change is introduced.

Intelligence Outlook

Monitor HSA's Health Products Alerts and product recall notices at hsa.gov.sg for any formal recall order, product seizure action, or expanded enforcement sweep targeting corticosteroid-adulterated herbal products following this case.